• Novalis Biotech Acceleration invests in San Francisco-based Modality.AI - technology that ‘self-drives’ neurological and psychiatric assessments

    Friday September 3rd 2021

  • Quality by Design zet nieuwe stap in groeiverhaal: Qarad vervoegt QbD Group

    Thursday September 2nd 2021

  • Biocartis launches Idylla™ SARS-CoV-2/Flu/RSV Panel

    Thursday September 2nd 2021

  • ExeVir announces first patient enrolled in phase 1b/2 clinical study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

    Wednesday September 1st 2021

  • Galapagos announces planned retirement of CEO

    Tuesday August 31st 2021

  • Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors

    Tuesday August 31st 2021

  • Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004

    Monday August 30th 2021

  • argenx announces validation of European marketing authorization application for Efgartigimod in generalized myasthenia gravis

    Wednesday August 25th 2021

  • Your news here?

  • Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science

    Tuesday August 17th 2021

  • Precirix enters into alliance with 3P Biopharmaceuticals for the manufacturing of single domain antibodies

    Tuesday August 17th 2021

  • Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017

    Wednesday July 28th 2021


Strategic Partners